{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:27Z","timestamp":1790983167023,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of NSCLC with EGFR mutations due to their efficacy and favourable safety profile. However, drug-induced liver injury (DILI) associated with targeted therapy may occasionally present with atypical clinical and radiological features, posing diagnostic challenges. Here, we present a rare case of severe hepatotoxicity accompanied by pseudo-progressive portal lymphadenopathy that occurred following furmonertinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 59-year-old female patient with EGFR-mutated NSCLC initiated treatment with the third-generation EGFR-TKI furmonertinib. Two months into the therapy, the patient developed jaundice and marked elevations in total bilirubin and transaminases. Extensive laboratory investigations excluded viral hepatitis and autoimmune liver diseases. Abdominal imaging revealed newly enlarged portal lymph nodes, mimicking malignant metastasis, but without clear evidence of hepatic metastasis or biliary obstruction. Furmonertinib was discontinued and systemic corticosteroid therapy was initiated. Within 2\u00a0weeks, liver function tests had improved significantly and follow-up imaging showed that the portal lymphadenopathy had regressed. Causality assessment using the RUCAMyielded a score of 9, indicating a highly probable drug-induced liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that severe hepatotoxicity associated with furmonertinib may present with portal lymphadenopathy that mimics disease progression. Clinicians should remain vigilant for this atypical hepatotoxicity when using EGFR-TKIs and promptly assess portal lymph node status upon the emergence of jaundice or abnormal liver function. The implementation of early intervention strategies may facilitate recovery and help avoid misinterpretation of imaging findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1827175","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:39:23Z","timestamp":1784785163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Corticosteroid-responsive portal lymphadenopathy mimicking malignant progression induced by furmonertinib in EGFR-mutated NSCLC: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Nengyang","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1102\/1470-7330.2008.0006","article-title":"Ultrasound of malignant cervical lymph nodes","volume":"8","author":"Ahuja","year":"2008","journal-title":"Cancer Imaging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/1759-7714.14556","article-title":"Osimertinib-related liver injury with successful osimertinib rechallenge: a case report","volume":"13","author":"Cheng","year":"2022","journal-title":"Thorac. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-Induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2214\/AJR.06.1403","article-title":"Diffusion-weighted MRI in the body: applications and challenges in oncology","volume":"188","author":"Koh","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/j.jtho.2020.07.015","article-title":"Dermatopathic lymphadenopathy mimicking disease progression during osimertinib treatment","volume":"15","author":"Kunimasa","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B11","first-page":"145","article-title":"Immune mechanisms of idiosyncratic drug-induced liver injury","volume":"3","author":"Mak","year":"2017","journal-title":"J. Clin. Transl. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ar.20681","article-title":"Lymph circulation in the liver","volume":"291","author":"Ohtani","year":"2008","journal-title":"Anat. Rec. Hob."},{"key":"B10","first-page":"295","article-title":"Idiosyncratic drug-induced liver injury (IDILI): potential mechanisms and predictive assays","volume":"18","author":"Roth","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanisms of idiosyncratic drug-induced liver injury","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1102\/1470-7330.2013.0056","article-title":"Review of ultrasonography of malignant neck nodes: greyscale, doppler, contrast enhancement and elastography","volume":"13","author":"Ying","year":"2014","journal-title":"Cancer Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","article-title":"Adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: an updated meta-analysis","volume":"19","author":"Zhou","year":"2024","journal-title":"Target Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"153903","DOI":"10.1016\/j.tox.2024.153903","article-title":"Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib","volume":"507","author":"Zhou","year":"2024","journal-title":"Toxicology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2007.11.010","article-title":"Mechanisms of cholestasis","volume":"12","author":"Zollner","year":"2008","journal-title":"Clin. Liver Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1827175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:39:24Z","timestamp":1784785164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1827175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":20,"alternative-id":["10.3389\/fphar.2026.1827175"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1827175","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1827175"}}